Cell-Permeable Peptide Inhibitors of JNK
Novel Blockers of β-Cell Death
- From the Division of Medical Genetics, Centre Hospitalier Universitaire Vaudois—University Hospital, 1011 Lausanne, Switzerland.
- Address correspondence and reprint requests to Christophe Bonny, PhD, Division of Medical Genetics, CHUV—University Hospital, 1011 Lausanne, Switzerland. E-mail: christophe.bonny{at}chuv.hospvd.ch .
Abstract
Stress conditions and proinflammatory cytokines activate the c-Jun NH2-terminal kinase (JNK), a member of the stress-activated group of mitogen-activated protein kinases (MAPKs). We recently demonstrated that inhibition of JNK signaling with the use of the islet-brain (IB) 1 and 2 proteins prevented interleukin (IL)-1β—induced pancreatic β-cell death. Bioactive cell-permeable peptide inhibitors of JNK were engineered by linking the minimal 20-amino acid inhibitory domains of the IB proteins to the 10-amino acid HIV-TAT sequence that rapidly translocates inside cells. Kinase assays indicate that the inhibitors block activation of the transcription factor c-Jun by JNK. Addition of the peptides to the insulin-secreting βTC-3 cell line results in a marked inhibition of IL-1β—induced c-jun and c-fos expression. The peptides protect βTC-3 cells against apoptosis induced by IL-1β. All-D retro-inverso peptides penetrate cells as efficiently as the L-enantiomers, decrease c-Jun activation by JNK, and remain highly stable inside cells. These latter peptides confer full protection against IL-1β—induced apoptosis for up to 2 weeks of continual treatment with IL-1β. These data establish these bioactive cell-permeable peptides as potent pharmacological compounds that decrease intracellular JNK signaling and confer long-term protection to pancreatic β-cells from IL-1β—induced apoptosis.
Footnotes
-
ATF, activating transcription factor; BSA, bovine serum albumin; ERK, extracellular-regulated kinase; FITC, fluorescein isothiocyanate; GFP, green fluorescent protein; GST, glutathione S-transferase; IB, islet-brain; IL, interleukin; JBD, JNK-binding domain; JIP, JNK-interacting protein; JNK, c-Jun NH2-terminal kinase; JNKI, JNK inhibitor; KRBH, Krebs-Ringer bicarbonate-HEPES; MAP, mitogen-activated protein; MAPK, MAP kinase; NF, nuclear factor; NO, nitric oxide; PBS, phosphate-buffered saline; PCR, polymerase chain reaction; PDX, pancreatic duodenal homeobox factor.
-
- Accepted October 2, 2000.
- Received July 31, 2000.
- by the American Diabetes Association, Inc.














